Blockchain Registration Transaction Record

Ventripoint Showcases AI Cardiac Imaging at AEPC 2026

Ventripoint Diagnostics exhibits at AEPC 2026, showcasing VMS+™ AI-powered cardiac imaging for congenital heart disease. Learn how this MRI-equivalent technology improves patient management.

This news matters because it highlights a significant advancement in the management of congenital heart disease (CHD), a lifelong condition affecting millions worldwide. Ventripoint's VMS+™ technology offers a non-invasive, affordable, and accurate alternative to MRI for assessing cardiac function, enabling earlier and more frequent monitoring. For patients with CHD, this means improved clinical outcomes through personalized care pathways, as clinicians can track changes in heart function over time with confidence. The integration of AI-driven analysis at the point of care reduces delays in diagnosis and treatment, potentially lowering healthcare costs and improving quality of life. As CHD patients live longer due to medical advances, tools like VMS+™ are essential for lifelong surveillance, making this innovation a game-changer in pediatric and congenital cardiology.